NCT00084825View on ClinicalTrials.gov

Docetaxel and Imatinib Mesylate in Treating Patients With Androgen-Independent Prostate Cancer and Bone Metastases That Progressed on the Docetaxel and Placebo Group of MDA-ID-030008

PHASE2CompletedINTERVENTIONAL
Enrollment

23

Participants

Timeline

Start Date

May 31, 2003

Primary Completion Date

July 31, 2006

Study Completion Date

June 30, 2008

Conditions
Metastatic CancerProstate Cancer
Interventions
DRUG

Docetaxel

30 mg/m\^2 IV on days 1, 8, 15, and 22 every 42 days

DRUG

Imatinib mesylate

600 mg orally daily

Trial Locations (3)

10021

Memorial Sloan-Kettering Cancer Center, New York

02115

Dana-Farber/Harvard Cancer Center at Dana Farber Cancer Institute, Boston

77030-4009

M.D. Anderson Cancer Center at University of Texas, Houston

All Listed Sponsors
collaborator

National Cancer Institute (NCI)

NIH

lead

M.D. Anderson Cancer Center

OTHER

NCT00084825 - Docetaxel and Imatinib Mesylate in Treating Patients With Androgen-Independent Prostate Cancer and Bone Metastases That Progressed on the Docetaxel and Placebo Group of MDA-ID-030008 | Biotech Hunter | Biotech Hunter